GTC Regains US Rights To Atryn From Lundbeck

GTC and Lundbeck said that ATryn is approved for the prevention of peri-operative and peri-partum thromboembolic events in patients with hereditary antithrombin deficiency (HD AT), a rare and potentially fatal blood clotting disorder.

Under the definitive agreement, GTC and Lundbeck have agreed to a defined transition period of up to six months wherein Lundbeck is expected to perform certain services on behalf of GTC in order to ensure that ATryn will continue to be available to physicians and their patients in an uninterrupted fashion as commercialisation responsibilities are smoothly transitioned to GTC.

Thereafter, Lundbeck is expected to get a royalty on net sales beginning in two years, with a predefined cumulative maximum.

William Heiden, chairman, president and CEO of GTC, said: “Our collaboration with Lundbeck has been excellent and I would like to thank the Lundbeck team which has worked so diligently on the successful launch of ATryn in the US.

“Both parties agree that it is now the right time and in the best interests of both companies, given their respective strategic objectives, to transfer ATryn rights back to GTC.

“We look forward to working through this transition with Lundbeck to ultimately take on full responsibility for the commercialisation of ATryn in the US. Looking to the future, GTC is committed to maximising the commercial potential for ATryn in the US marketplace.”